BL
BLTE.US Belite Bio Inc ADR
- Market cap
- USD 6.49B
- P/E
- -
- P/B
- 8.87x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BLTE.US undervalued?
Graham numberThe Graham number of Belite Bio Inc ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Belite Bio Inc ADR fundamental analysis
No fundamental analysis for Belite Bio Inc ADR yet.
Belite Bio Inc ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009,…
Full company profileBelite Bio Inc ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Belite Bio Inc ADR annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -17.0K | -30.0K | -198K | -399K | -449K | - | - |
| Operating Income | -5.74M | -9.80M | -12.8M | -31.7M | -40.0M | -84.2M | -139M |
| EBITDA | -5.73M | -9.64M | -12.4M | -31.2M | -35.7M | -77.1M | -132M |
| Net Income | -5.75M | -9.67M | -12.6M | -31.6M | -36.1M | -77.6M | -114M |
| EPS | -0.62 | -0.40 | -0.63 | -1.19 | -1.18 | -2.31 | -2.82 |
| Balance Sheet | |||||||
| Total Assets | 25.7M | 18.3M | 44.3M | 94.6M | 152M | 781M | - |
| Total Liabilities | 32.8M | 33.4M | 2.77M | 4.21M | 6.31M | 10.1M | - |
| Shareholders' Equity | -7.04M | -15.1M | 41.5M | 90.4M | 146M | 770M | - |
| Cash & Short-term Investments | 25.6M | 17.3M | 42.1M | 88.2M | 145M | 492M | - |
| Total Debt | 31.8M | 31.8M | 866K | 886K | 537K | 429K | - |
| Cash Flow | |||||||
| Operating Cash Flow | -4.44M | -7.47M | -11.5M | -29.8M | -29.2M | -37.0M | - |
| Capital Expenditure | 20.0K | 74.0K | 394K | 63.0K | 151K | 178K | 0.00 |
| Free Cash Flow | -4.46M | -7.55M | -11.9M | -29.9M | -29.4M | -37.2M | - |
| Ratios | |||||||
| ROE | - | - | -30.5% | -35.0% | -24.8% | -10.1% | - |
| ROA | -22.3% | -52.7% | -28.6% | -33.4% | -23.8% | -9.9% | - |
| Debt to Equity | - | - | 0.02x | 0.01x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Belite Bio Inc ADR dividends
Belite Bio Inc ADR has not paid dividends in the last 6 fiscal years.
Who owns Belite Bio Inc ADR
- Insiders 43.70%
- Institutions 24.22%
- Public & others 32.08%
- Shares outstanding 40.3M
- Free float 19.5M
Top funds holding BLTE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 391K | 0.97% | +9.28% | Jun 2026 |
| T. Rowe Price Health Sciences | 158K | 0.39% | 0.00% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 80.9K | 0.20% | -17.01% | Aug 2026 |
| State Street® SPDR® Portfolio EM ETF | 29.9K | 0.07% | 0.00% | Oct 2026 |
| apo Medical Opportunities R | 21.9K | 0.05% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 13.3K | 0.03% | 0.00% | Jul 2026 |
| RIM Global Bioscience EUR | 12.8K | 0.03% | 0.00% | Jul 2026 |
| T. Rowe Price Health Sciences Port | 10.1K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 6.73K | 0.02% | 0.00% | Aug 2026 |
| TD Health Sciences - I | 6.51K | 0.02% | -26.95% | Jun 2026 |
| Fidelity ZERO International Index | 6.29K | 0.02% | +6.07% | Sep 2026 |
| ActivePassive International Equity ETF | 4.21K | 0.01% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite ETF | 3.76K | 0.01% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® China ETF | 3.19K | 0.01% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 3.10K | 0.01% | 0.00% | Aug 2026 |
| EQ/T. Rowe Price Health Sciences IB | 2.50K | 0.01% | +108.33% | Sep 2026 |
| Fidelity Flex International Index | 2.09K | 0.01% | 0.00% | Sep 2026 |
| Virtus Biotech Clinical Trials ETF | 1.93K | 0.00% | 0.00% | Oct 2026 |
| JHVIT Health Sciences I | 1.68K | 0.00% | -20.40% | Aug 2026 |
| Even Herd Long Short ETF | 1.29K | 0.00% | 0.00% | Oct 2026 |
Top institutions holding BLTE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.08M | 7.64% | +0.65% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 1.23M | 3.06% | +10.59% | Jun 2026 |
| RTW INVESTMENTS, LLC | 715K | 1.78% | 0.00% | Jun 2026 |
| Millennium Management LLC | 495K | 1.23% | -13.25% | Jun 2026 |
| Maverick Capital Ltd | 396K | 0.98% | 0.00% | Jun 2026 |
| Eventide Asset Management, LLC | 391K | 0.97% | +9.28% | Jun 2026 |
| Deerfield Management Co | 357K | 0.89% | +17.49% | Jun 2026 |
| Holocene Advisors, LP | 251K | 0.62% | -49.23% | Jun 2026 |
| Logos Global Management LP | 250K | 0.62% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 235K | 0.58% | +16.71% | Jun 2026 |
| UBS Group AG | 225K | 0.56% | -70.72% | Jun 2026 |
| Citadel Advisors Llc | 186K | 0.46% | +9,171.31% | Jun 2026 |
| The Goldman Sachs Group Inc | 166K | 0.41% | +57.51% | Jun 2026 |
| Affinity Asset Advisors, LLC | 165K | 0.41% | +153.85% | Jun 2026 |
| MPM Oncology Impact Management LP | 137K | 0.34% | +55.84% | Jun 2026 |
| Bank of America Corp | 125K | 0.31% | +3,202.89% | Jun 2026 |
| Patient Square Capital LP | 110K | 0.27% | -5.73% | Jun 2026 |
| Duquesne Family Office LLC | 106K | 0.26% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 106K | 0.26% | -62.44% | Jun 2026 |
| Jane Street Group LLC | 65.8K | 0.16% | +438.38% | Jun 2026 |
Belite Bio Inc ADR company profile
- Company name
- Belite Bio Inc ADR
- Ticker
- BLTE.US
- Exchange
- USA Stocks
- Listed since
- Apr 29, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Fiscal year end
- December
- Address
- 12750 High Bluff Drive, San Diego, CA, United States, 92130
- Phone
- 858 246 6240
- Website
- belitebio.com
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Belite Bio Inc ADR management
5- Dr. Yu-Hsin Lin M.B.A., Ph.D.Chairman of the Board of Directors & CEO · born 1978
- Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A.CFO & Director · born 1984
- Dr. Nathan L. Mata Ph.D.Chief Scientific Officer · born 1966
- Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D.Chief Medical Officer · born 1969
- Ms. Kelly KilpatrickChief Commercial Officer